Cellares, an Integrated Development and Manufacturing Organization (IDMO), has appointed Ali Soleymannezhad as Chief Commercial Officer.

Soleymannezhad, formerly Chief Commercial Officer at MaxCyte and Executive Vice President at Tosoh Bioscience, will lead global commercial strategy as the company deploys its network of IDMO Smart Factories across the United States, Europe, and Japan. His appointment is key to driving the commercial expansion and pipeline growth in preparation for a future IPO.

Soleymannezhad brings more than two decades of experience building global commercial organizations around advanced life-science platforms. At MaxCyte, he led commercial strategy and execution across sales, business development and licensing, marketing, product management, and field applications, expanding adoption across the United States, Europe, and Asia while securing enterprise and partner agreements with leading biopharmaceutical companies.

At Tosoh Bioscience, he directed global strategy and P&L, securing multi-year supply agreements that embedded the company’s technologies into critical bioprocessing workflows. At Cellares, he will leverage his experience to secure long-term, multi-program partnerships that anchor sponsors’ cell therapy portfolios on Cellares’ IDMO Smart Factories and expand patient access to life-changing therapies.

Soleymannezhad holds an MBA from Rice University and B.E.Sc. and M.E.Sc. Degrees in Chemical and Biochemical Engineering from Western University.

“Throughout my career, I’ve worked to bring breakthrough technologies to patients, but Cellares is different,” said Ali Soleymannezhad. “Too many patients miss out on life-changing cell therapies because global manufacturing capacity simply can’t keep pace. With Cellares’ first-of-its-kind Cell Shuttle and global IDMO infrastructure, we finally have the ability to meet total patient demand. I’m honored to join Cellares on this mission, and am committed to ensuring that every therapy capable of transforming lives can actually reach the patients who need it.”

As Chief Commercial Officer, Soleymannezhad will oversee global enterprise sales, business development and licensing, and strategic marketing. He will partner with biopharmaceutical companies to build multi-year, multi-program portfolios that leverage Cellares’ IDMO Smart Factories as shared global infrastructure for current and future cell therapy programs.